title: [Omaron in the complex treatment of patients with multiple sclerosis].
abstract: We studied efficacy and tolerability of the combined drug omaron (25 mg of cinnarizine and 400 mg of piracetam in one tablet) in patients with multiple sclerosis. The dosage of the drug was 1 tablet 3 times a day during 12 weeks in 33 patients (mean age 35.3±4.2 years) of the index group. A comparison group consisted of 27 patients matched for demographic and clinical characteristics who did not receive nootropics during the study. None of patients included in the study received disease modifying drugs. The significant (p<0.05) decrease in the severity of chronic fatigue syndrome (by 28.6% compared to baseline), improvement (p<0.05) of cognitive functions (increase of MMSE scores by 9.4%) were found in the index group compared to the comparison one. The statistically significant changes in the severity of disability assessed by EDSS were not observed. Omaron was well-tolerated with no serious adverse-effects.
authors.forename: N F
authors.initials: NF
authors.lastname: Popova
authors.forename: P R
authors.initials: PR
authors.lastname: Kamchatnov
authors.forename: O V
authors.initials: OV
authors.lastname: Riabukhina
authors.forename: T T
authors.initials: TT
authors.lastname: Batysheva
authors.forename: K A
authors.initials: KA
authors.lastname: Zaĭtsev
authors.forename: A N
authors.initials: AN
authors.lastname: Boĭko
mesh_terms: D000328:Adult; D002936:Cinnarizine / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D015673:Fatigue Syndrome, Chronic / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000150:complications / Q000188:drug therapy*; D010889:Piracetam / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D004338:Drug Combinations; D002936:Cinnarizine; D010889:Piracetam